SecBot SecBot
DEFA14A ·Filed Aug 19, 2026

SKYE

Skye Bioscience, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed2mo ago SEC0001628280-26-058121
Proxy solicitation materials
Actionable Insight • Neutral

The reverse split is a technical event; the real catalyst is the Redx Pharma acquisition. Traders should monitor the upcoming proxy statement filing and the special meeting vote, as stockholder approval is required to close the deal. The reverse split date (Aug 24) may cause short-term volatility as the market adjusts to the new share price, but the long-term thesis hinges on the Redx transaction closing.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.2809
T+0 close · Aug 19, 2026 · via day close
Latest settled
−51.50%
T+60 · $0.1363
Vs SPY
−50.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $0.2809entry
  2. T+1 · 3mo ago −0.32%α −0.73% · $0.2800
  3. T+5 · 3mo ago −13.23%α −14.34% · $0.2437
  4. T+20 · 2mo ago −21.46%α −21.34% · $0.2206
  5. T+60 · 4d ago −51.50%α −50.42% · $0.1363
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience filed a DEFA14A to announce the effective date of its previously disclosed 1-for-8 reverse stock split, set for August 24, 2026, as part of its efforts to regain Nasdaq compliance. This filing is a procedural step in the broader transformative acquisition of Redx Pharma, which will fundamentally change Skye's business and capital structure. The reverse split is a technical event that does not alter the company's fundamentals but is necessary to maintain its listing ahead of the Redx deal.

Key Facts

  • The 1-for-8 reverse stock split will become effective at 12:01 am New York time on Thursday, August 24, 2026.
  • Common stock will begin trading on a split-adjusted basis at market open on August 24, 2026, under the same ticker symbol SKYE.
  • The new CUSIP number for the common stock following the reverse split is 83086J309.
  • This filing is an amendment to the Original Form 8-K filed August 14, 2026, which disclosed the transaction agreement to acquire Redx Pharma Limited.
  • The reverse split is intended to help Skye regain compliance with Nasdaq's minimum bid price requirement.

Financial Impact

The reverse stock split is a mechanical adjustment with no change to the company's market capitalization or enterprise value. The transaction to acquire Redx Pharma values Redx at $161 million and includes a concurrent $125 million PIPE.

share priceoutstanding shares

Risk Factors

  • The Redx acquisition may not close if stockholder approval is not obtained or other closing conditions are not satisfied.
  • The reverse split may not be sufficient to maintain Nasdaq listing if the post-split share price does not stay above $1.00.
  • Current SKYE shareholders face significant dilution and a change of control, with Redx designating the post-closing board and management.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-058121
Document: 0001628280-26-058121-index-headers.html0001628280-26-058121
Document: 0001628280-26-058121-index.html0001628280-26-058121
Document: 0001628280-26-058121.txt0001628280-26-058121

Track record

16 reports on SKYE

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Viewing Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026